Lilly to Initiate Phase 3 Clinical Trial Enrollment for Eloralintide in Obesity Treatment Following Positive Phase 2 Results

Gelonghui November 12 | Eli Lilly and Company announced positive results from the Phase 2 clinical study of eloralintide, an investigational selective amylin receptor agonist administered once weekly. The study evaluated the safety and efficacy of eloralintide in 263 obese or overweight adult participants without type 2 diabetes but with at least one weight-related comorbidity. At week 48, all dose groups of eloralintide met the primary endpoint, with an average weight reduction ranging from 9.5% to 20.1%, surpassing the placebo group’s average reduction of 0.4% (using the efficacy estimand). Based on these trial results, Eli Lilly plans to initiate enrollment for the Phase 3 clinical study of eloralintide for obesity treatment the following month.